Depending on the criteria used to define ER and PGR positivity and the techniques employed for HER2 assessment, these tumors make up 10–17% of all breast carcinomas [32,34,50,51,52,53,54,55,56,57]. The gene discussed is ERBB2; the disease is breast carcinoma.